Table 1 Patient and tumor characteristics
From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Characteristic | All (n = 38) | Cohort 1 (HER2-negative) (n = 9) | Cohort 2 (HER2-positive) (n = 29) |
|---|---|---|---|
No. of patients (%) | No. of patients (%) | No. of patients (%) | |
Age, years | |||
 Median (range) | 48 (31–62) | 46 (31–57) | 48 (32–62) |
Sex | |||
 Female | 38 (100) | 9 (100) | 29 (100) |
 Male | 0 (0) | 0 (0) | 0 (0) |
Race | |||
 White | 34 (89) | 8 (89) | 26 (90) |
 Black or African-American | 1 (3) | 1 (11) | 0 (0) |
 Asian | 3 (8) | 0 (0) | 3 (10) |
Ethnicity | |||
 Hispanic or Latino | 1 (3) | 0 (0) | 1 (3) |
 Non-Hispanic | 37 (97) | 9 (100) | 28 (97) |
ECOG PS at baseline | |||
 0 | 24 (63) | 4 (44) | 20 (69) |
 1 | 9 (24) | 3 (33) | 6 (21) |
 2 | 5 (13) | 2 (22) | 3 (10) |
Stage at initial diagnosis | |||
 I | 5 (13) | 1 (11) | 4 (14) |
 II | 13 (34) | 4 (44) | 9 (31) |
 III | 7 (18) | 1 (11) | 6 (21) |
 IV | 13 (34) | 3 (33) | 10 (34) |
Receptor status at initial diagnosis | |||
 ER and/or PR+, HER2-negative | 7 (18) | 5 (56) | 2 (7)b |
 ER and/or PR+, HER2-positive | 14(37) | 1 (11)a | 13 (45) |
 ER and PR negative, HER2-positive | 14(37) | 0 (0) | 14 (48) |
 ER, PR, and HER2-negative | 3 (8) | 3 (33) | 0 (0) |
Disease-free interval | |||
  < 2 years | 22 (58) | 7 (78) | 15 (52) |
  > 2 years | 16 (42) | 2 (22) | 14 (48) |
Interval from metastatic diagnosis to CNS diagnosis (median [months], range) | 14.8 (0–107) | 5.9 (0–44.7) | 16.6 (0–107) |
Interval from CNS diagnosis to study entry (median [months], range) | 15.7 (0.2–63.6) | 11.0 (0.4–25.5) | 19.8 (0.2–63.6) |
Number of metastatic disease sites (median, range) | 4 (1–5) | 4 (1–5) | 4 (1–5) |
Sites of disease | |||
 CNS | 38 (100) | 9 (100) | 29 (100) |
 Lung or pleural effusion | 19 (50) | 6 (67) | 13 (45) |
 Liver | 17 (45) | 4 (44) | 13 (45) |
 Bone | 26 (68) | 7 (78) | 19 (66) |
 Breast or chest wall | 5 (13) | 1 (11) | 4 (14) |
 Other | 15 (39) | 4 (44) | 11 (38) |
| Â | Median (range) | Median (range) | Median (range) |
Baseline CNS disease volume (in cc) | 5.3 (0.7, 58.8) | 8.2 (2.1, 24.7) | 3.6 (0.7, 58.8) |
| Â | No. of patients (%) | No. of patients (%) | No. of patients (%) |
Number of target CNS lesions | |||
 1 | 9 (24) | 2 (22) | 7 (24) |
 2 | 14 (37) | 2 (22) | 12 (41) |
 3 | 7 (18) | 3 (33) | 4 (14) |
 4 | 6 (16) | 1 (11) | 5 (17) |
 5 | 2 (5) | 1 (11) | 1 (3) |
| Â | Median (range) | Median (range) | Median (range) |
Size of target CNS lesions (in mm) | 15.4 (10, 60.5) | 16 (11.7, 40.9) | 14.4 (10, 60.5) |